CG Oncology (CGON) Projected to Post Earnings on Friday

CG Oncology (NASDAQ:CGON) will likely be posting its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect CG Oncology to post earnings of ($0.61) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 27, 2026 at 8:30 AM ET.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings results on Friday, February 27th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.10. The firm had revenue of $2.32 million for the quarter. On average, analysts expect CG Oncology to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CG Oncology Stock Down 1.7%

Shares of CGON opened at $63.84 on Wednesday. The stock has a market capitalization of $5.39 billion, a P/E ratio of -30.84 and a beta of 1.18. CG Oncology has a twelve month low of $14.80 and a twelve month high of $69.35. The firm has a fifty day simple moving average of $57.33 and a two-hundred day simple moving average of $46.65.

Insider Activity

In other news, Director James Mulay sold 1,964 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $63.50, for a total value of $124,714.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Institutional Trading of CG Oncology

A number of large investors have recently modified their holdings of the company. Voleon Capital Management LP bought a new stake in CG Oncology during the 3rd quarter valued at $410,000. Creative Planning bought a new position in shares of CG Oncology during the 3rd quarter worth $284,000. Virtus Investment Advisers LLC increased its stake in shares of CG Oncology by 51.3% during the fourth quarter. Virtus Investment Advisers LLC now owns 6,497 shares of the company’s stock valued at $270,000 after buying an additional 2,203 shares during the period. Federated Hermes Inc. increased its stake in shares of CG Oncology by 20.0% during the second quarter. Federated Hermes Inc. now owns 10,200 shares of the company’s stock valued at $265,000 after buying an additional 1,700 shares during the period. Finally, LPL Financial LLC raised its holdings in shares of CG Oncology by 9.8% in the fourth quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock valued at $257,000 after acquiring an additional 551 shares in the last quarter. Hedge funds and other institutional investors own 26.56% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on CGON shares. Piper Sandler increased their price objective on CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. Truist Financial raised their target price on CG Oncology from $66.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. The Goldman Sachs Group restated a “buy” rating and set a $82.00 target price on shares of CG Oncology in a report on Monday, January 12th. Finally, Royal Bank Of Canada boosted their price objective on shares of CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, CG Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $69.00.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.